Results of phase II and phase III trials with new aromatase inhibitors

[1]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Howell,et al.  A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.

[3]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Y. Ohashi,et al.  373 Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer , 1995 .

[5]  P. Lønning,et al.  2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer , 1995 .

[6]  A. Buzdar,et al.  104. Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer , 1995 .

[7]  A. Howell,et al.  3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC) , 1995 .

[8]  M. Dowsett,et al.  ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  J. Cidlowski,et al.  Regulation of apoptosis by steroid hormones , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  R. Santen,et al.  Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.

[11]  L. Tye,et al.  Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  M. Dowsett,et al.  Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. , 1994, Cancer research.

[13]  J. Wolter,et al.  Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen , 1994, Cancer.

[14]  P. Queirolo,et al.  Second‐Line Hormonotherapy for Breast Cancer: Uselessness of First‐Line Continuation , 1993, American journal of clinical oncology.

[15]  V. Gebski,et al.  Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Blankenstein,et al.  Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. , 1993, Cancer research.

[17]  S. Ebbs,et al.  Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  K. Höffken.  Experience with aromatase inhibitors in the treatment of advanced breast cancer. , 1993, Cancer treatment reviews.

[19]  R. Santen,et al.  The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  R. Santen,et al.  The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer , 1993, Journal of Steroid Biochemistry and Molecular Biology.

[21]  M. Dowsett,et al.  Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. , 1993, Cancer research.

[22]  P. Lønning,et al.  Aromatase Inhibitors in Malignant Diseases of Aging , 1992, Drugs & aging.

[23]  J. Raats,et al.  Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  J. Garcia-conde,et al.  Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Santen.  Clinical use of aromatase inhibitors in human breast carcinoma , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  J. Garber,et al.  Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. , 1991, The Journal of clinical endocrinology and metabolism.

[27]  M. Lang,et al.  Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  C. Bowden,et al.  New non-steroidal aromatase inhibitors: Focus on R76713 , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  C. Spurr,et al.  High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Raeymaekers,et al.  R 76713, a new specific non-steroidal aromatase inhibitor. , 1989, Journal of steroid biochemistry.

[31]  W. Miller.  Aromatase inhibitors in the treatment of advanced breast cancer. , 1989, Cancer treatment reviews.

[32]  P. Canney,et al.  Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast Carcinomau , 1988 .

[33]  J. Ingle,et al.  Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Ingle,et al.  Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. , 1982, American journal of clinical oncology.

[35]  T. Powles,et al.  Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. , 1994, European journal of cancer.

[36]  G. Failla,et al.  Megestrol acetate (MGA) plus alpha 2A interferon (IFN) as second line therapy in patients (pts) with advanced breast cancer (a.b.c.): Preliminary results of a multicentric phase II trial , 1993 .